| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8776827 | The Breast | 2018 | 7 Pages |
Abstract
This study showed that MammaPrint classified 52.6% of clinical high risk tumors as genomic low risk. In the Netherlands, 62.7% of the MammaPrint assays from 2013 to 2016 were performed on clinical low risk tumors, although recent International Guidelines recommend its use in clinical high and intermediate risk tumors.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Floris H. Groenendijk, Agnes Jager, Fatima Cardoso, Carolien H.M. van Deurzen,